✦ LIBER ✦

NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer

✍ Scribed by Bernice Dillon; Bhash Naidoo; Helen Knight; Peter Clark

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

NICE guidance on erlotinib for the maint

✍ Fiona Rinaldi; Elisabeth George; Peter Clark 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 52 KB

26 Audit of gefitinib for the first-line

✍ Douglas, R.; Campbell, L.; McAleese, J.; Scullin, P. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 43 KB

PCN7 COMPARATIVE EFFECTIVENESS ASSESSMEN

✍ B. Schwander; J. de Castro Carpeño; D.F. Heigener; E. Wright; H.G. Bischoff; S. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

PCN110 Economic Evaluation of Gefitinib

✍ Fragoulakis, V.; Pallis, A.; Kourlaba, G.; Georgoulias, V.; Maniadakis, N. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

P-485 EGFR mutations do not accurately p

✍ Giaccone, G.; Janmaat, M.; Gallegos Ruiz, M.; Rodriguez, J.; LeChevalier, T.; Th 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Egfr Test-Guided Erlotinib Versus Chemot

✍ Bajaj, P.S.; Carlson, J.J.; Goertz, H.P.; Veenstra, D.L. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB